Totally Implantable Venous Access Devices In Pediatric Surgery Patients.
- Author:
Sung Eun JUNG
1
;
Yoon Ho KIM
;
Yong Sun JUN
;
Dae Yeon KIM
;
Jong Kwon PARK
;
Seong Cheol LEE
;
Kwi Won PARK
;
Woo Ki KIM
Author Information
1. Department of Surgery, Seoul National University College of Medicine, Korea.
- Publication Type:Original Article
- Keywords:
Totally implantable venous access system
- MeSH:
Child;
Drug Therapy;
Humans;
Infant;
Subclavian Vein;
Thrombosis;
Veins;
Wounds and Injuries
- From:Journal of the Korean Surgical Society
1997;52(3):420-425
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Long-term venous access devices have become an important part of the stantard care for children with malignant disease requiring chemotherapy. Totally implantable venous access system(TIVAS) gained widespread use and acceptance in the management of children with cancer in whom frequent and prolonged venous access is required. We analysed our experiences of insertion and use of totally implantable venous access device in 70 pediatric patients(79 devices), between April 1991 and April 1996. Median age of patients was 6 years and 10 months old. Median duration of utilization was 320 days(range 7-1449 days). Access vein was right external jugular vein(46.8%), left external jugular vein(21.5%), right internal jugular vein(11.4%), left internal jugular vein(3.8%), right subclavian vein(1.3%), left subclavian vein (7.6%), right cephalic vein(2.5%), left cephalic vein(5.1%). Complications related to surgical factors included: wound dehiscence(3 cases), hematoma(1 case), malposition of catheter(1 case). Complications not related to surgical factors included: occlusion of catheter(12 cases), wound infection(7 cases), sepsis(6 cases), leakage(3 cases), hematoma(3 cases), thrombosis of vein (1case). Many complications resolved spontaneously or with medical threatment and 14 cases(17.7%) required removal of system. We conclude that with long-term usage of totally implantable venous access system making it a safe and viable alternative for patients requiring long-term intravenous therapy.
